Management of the adverse effects associated with intravenous bisphosphonates. - Wikidata - awgldk - TriplyDB

Management of the adverse effects associated with intravenous bisphosphonates.

Management of the adverse effects associated with intravenous bisphosphonates.

http://www.wikidata.org/entity/Q36425229

about

Bisphosphonates in multiple myeloma: a network meta-analysis Bisphosphonates in multiple myeloma Hypercalcemia of malignancy and new treatment options Bisphosphonate Related Osteonecrosis of the Jaw: An Update Pain related to cancer treatments and diagnostic procedures: a no man's land?Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial.Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis.Potential pathophysiological mechanisms in osteonecrosis of the jaw.Synthesis, characterization and in vitro evaluation of new composite bisphosphonate delivery systems.Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment.Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.Side effects of bone-targeted therapies in advanced breast cancer.Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats.Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid.Treatment of immobilization-related hypercalcaemia with denosumab.Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?Severe polyarthritis secondary to zolendronic acid: a case report and literature review Current approaches to bone-targeted therapy in genitourinary malignancies Importance of antiresorptive therapies for patients with bone metastases from solid tumors.Nutrition support and the chronic critical illness syndrome.Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.Zoledronic acid in the management of metastatic bone disease.Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.The safety of zoledronic acid.Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.Significance and impact of bisphosphonate-induced acute phase responses.Evaluation of socket healing in patients undergoing bisphosphonate therapy: experience of a single Institution.Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients.Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.Treatment options for breast cancer and bone metastases.The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates The use of zoledronic acid in pediatric cancer patients.New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.Soluble molecules and bone metabolism in multiple myeloma: a review.Prescribing of zoledronic acid in a tertiary outpatient hospital setting.Evolution and etiopathogenesis of bisphosphonates induced osteonecrosis of the jaw

P2860

Q24197839-0A3AB0DC-A0FD-46DF-95C7-BD7424FC9213 Q24236776-8C627836-088C-4FD5-91DE-FDF3BE9AFC14 Q26775300-12BD2439-0141-4DF3-B509-574769663EFE Q26801664-AD940C2A-8FC0-44B9-8B2E-3C90E56E536F Q27026749-E7928B23-BF4B-49D4-A27F-DE8BCC7EC792 Q33746674-A887E7A4-3FF1-4C2E-96E8-03A3FFA23368 Q33886852-BC7ED458-4986-40E4-A434-3F4F01F2CF69 Q34162359-0E2CC89B-2476-414B-8C58-15C290BFEFE4 Q34359069-53D8AE9F-FC0D-4A1E-B1CE-59C12CBDE754 Q34631769-B4DA9A1B-AF54-486D-9BB6-462433AF1D54 Q35026446-48535BE4-FD0A-4883-B883-08DC09F9E778 Q35066955-D147ED44-686B-4976-9A17-7699996A82E2 Q35093824-E9BF7981-BA4B-4359-B563-2E4DC700FFB3 Q35155516-0252841F-EFCD-4DC4-981D-53131362377E Q35309369-B8EA4843-BA86-4897-854A-E6D17DDB103C Q35453039-3DA9DE06-6F8B-4E61-A15E-225165610912 Q35583788-741BDA47-53B4-4D59-AD5B-1D0F05760CB8 Q35624101-57938686-2F5B-4941-8EF1-56BAE2C083CA Q35747575-48F208E3-3034-435D-91F8-C5B556D56E76 Q36231718-3FC1D5E7-E230-43BD-AD2F-8F50B6DAA3A8 Q36283738-37F3D2B1-A80F-45E3-8D9F-5A7328F43C5F Q36659996-1F6BF02A-6102-4A71-B860-EBE3ABE6DEEC Q36696468-C542F9A6-2EC7-495B-BB95-7739E4F42212 Q36708315-304ADBB6-7566-4845-B11A-B3E37862565A Q36710276-A6210F14-AB7A-4DE3-B7AB-D8428B81EBC9 Q36811542-20BEAACF-CEA7-4B04-88F8-1212D07F4997 Q36979311-E37B4324-3903-4BA1-B67F-D0F3F47A187D Q37018333-FB7A3D45-CA13-4F7E-A702-AF56A39A742C Q37063582-6CF07A26-BADE-4792-96B1-20856A453417 Q37098197-4B207AFB-88A2-45BE-B260-E747EC5B7FEF Q37123420-6CC57CB0-E035-46CB-B3F6-B6793E8951BF Q37401841-020E5421-E56F-48C9-9391-9A18FDC05D49 Q37493951-0FC6AA5D-DC7B-4510-9460-E10D037BABB7 Q37598932-835A3E1A-6ECD-4A40-9501-DB5C1AE7D9B8 Q37731222-B7046B17-5A7A-4082-9E91-54BC58668427 Q37836669-E371A019-3A87-4346-9697-06ED5A15C3FA Q37917774-70FC87BD-E1E4-48C6-825A-8CA3CF8B2846 Q37998401-7911279F-4B4A-463E-9016-0BA48DD29199 Q38041483-819F234E-9E69-400D-BD49-F975AD39077A Q38110805-D09019F2-DC6E-45AE-96EE-EBB6A1A6C9A8

P2860

Management of the adverse effects associated with intravenous bisphosphonates.

http://www.wikidata.org/entity/Q36425229

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Management of the adverse effects associated with intravenous bisphosphonates.

@ast

Management of the adverse effects associated with intravenous bisphosphonates.

@en

type

label

Management of the adverse effects associated with intravenous bisphosphonates.

@ast

Management of the adverse effects associated with intravenous bisphosphonates.

@en

prefLabel

Management of the adverse effects associated with intravenous bisphosphonates.

@ast

Management of the adverse effects associated with intravenous bisphosphonates.

@en

P1433

Q36425229-61A911EE-73C8-49FA-9C61-AA888B0F395F

P1476

Q36425229-374F97E4-C28A-4340-BE5E-FCDBB3BCFF07

P2093

Q36425229-2B88134B-5179-4DED-864F-4A1149D747CE

Q36425229-AFF43488-6875-4442-9958-3968D9EF4408

P2860

Q36425229-176B5558-7588-4151-9772-DADFDDDB6ADC

Q36425229-264E583D-020A-4D89-BCED-0B1193CCFFF4

Q36425229-6DF0C58F-E44D-45F9-81D2-E24A7B993AED

Q36425229-7ABB8B21-117D-4595-8341-6AF0587F2146

Q36425229-957FEB13-1166-45EF-B19D-6023EEF1AAF1

Q36425229-A66A8FD6-F1BA-4B8D-98D3-B3DFA51050D5

Q36425229-D10466DA-1D42-43CA-A8AC-2D4713F35C59

Q36425229-F051F514-669E-41D1-A52D-B69480FB0868

Q36425229-FFAAAB67-A9AC-4318-9926-991809404639

P304

Q36425229-450F15EE-8B46-45A0-A8CE-25FB2EF42A93

P31

Q36425229-0F2C5DD4-F1D0-486E-BD70-3755AB25B238

P356

Q36425229-B29AFE96-8390-40D0-A691-6B66722EDDFB

P433

Q36425229-EC8B3A2E-2886-48D1-9C18-C19D05DA461C

P478

Q36425229-4247E0EE-73FC-4D03-95F8-0A023D4CA569

P577

Q36425229-D5E80079-C0E7-48C1-AF49-69F988CF6D49

P5875

Q36425229-E1B16154-040C-4410-A527-BBCFB84DBE33

P698

Q36425229-CBF1AE5F-A5B1-4808-B1E7-8CB7C460728F

P356

P1433

Annals of Oncology

P1476

Management of the adverse effects associated with intravenous bisphosphonates.

@en

P2093

P J Stiff

http://www.w3.org/2001/XMLSchema#string

T Tanvetyanon

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Clodronate induced uveitis.

Evaluation of adverse experiences related to pamidronate infusion in Paget's disease of bone.

Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.

Idiopathic orbital inflammation following intravenous pamidronate.

Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.

Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma.

Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

Ask us: Some drugs affect tooth movement.

P304

897-907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDJ105

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7231990

http://www.w3.org/2001/XMLSchema#string

P698

16547070

http://www.w3.org/2001/XMLSchema#string